While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...
Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...
Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...
Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...
Nanobiotix and Johnson & Johnson’s radiotherapy-activated drug, JNJ-1900, has triggered an ORR of 69% during a Phase I trial in oesophageal cancer. Image credit: Kateryna Kon via ShutterStock.com.
Amgen is set to present the full data at the American Heart Association Scientific Sessions on 8 November. Image credit: Melnikov Dmitriy / Shutterstock.com. Amgen is hopeful that Phase III data will ...
The therapy demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. Credit: PeopleImages / Shutterstock.com. SCYNEXIS has ...
Results indicated 10.6% of Winrevair subjects experienced a minimum of one clinical worsening event, compared to 36.9% in placebo. Credit: Sai Thaw Kyar / Shutterstock.com. MSD has announced positive ...
FTD manifests in individuals aged 45 to 64 years. Credit: Komsan Loonprom / Shutterstock.com. Coya Therapeutics has completed participant enrolment of an investigator-initiated, open-label trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback